July 22, 2019
Two students from Lomonosov Moscow State University (MSU) did their master’s dissertations in InSysBio and successfully graduated from MSU in July. Stepan Lerner defended master thesis entitled “Mathematical model of the beta amyloid influence on synaptic transmission” supervised by Tatiana Karelina, Expert Modeler, lead Alzheimer’s Disease Modeling Consortium. Dmitry Shchelokov defended master thesis entitled “Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies” supervised by Oleg Demin Jr, Head of Business Development of InSysBio and Expert Modeler.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative approach has already become a part of the drug development process implemented by our strategic partners: nowadays there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. The company has published multiple scientific studies in various therapeutic areas. InSysBio team is developing software and tools for QSP and continuously improves methods for biological modeling. For more information about InSysBio, its solutions and services, visit insysbio.com.
| ← | September 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
1.
28 Sep 2017 19:27
Computer model showed an optimal anti-amyloid treatment
Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.
|
29
|
30
| |
Thank you for your message! We will get back to you shortly.
